TY - JOUR
T1 - Low Serum 3-Methylhistidine Levels Are Associated With First Hospitalization in Kidney Transplantation Recipients
AU - Lai, Yu Hsien
AU - Lee, Ming Che
AU - Lin, Tsung Jen
AU - Liu, Chin Hung
AU - Hsu, Bang Gee
N1 - Funding Information:
This study was supported by a grant from Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan (TCRD107-56). The authors would like to thank Enago (www.enago.tw) for the English language review.
Funding Information:
This study was supported by a grant from Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan ( TCRD107-56 ). The authors would like to thank Enago ( www.enago.tw ) for the English language review.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/12
Y1 - 2020/12
N2 - Background: Low protein intake and increased muscle breakdown are associated with increased mortality risk in patients with kidney transplantation (KT). 3-methylhistidine (3-MH), a nonproteinogenic amino acid residue, is an index of muscle breakdown. the present study investigated the association between serum 3-MH levels and subsequent first hospitalization events in patients with KT. Methods: A total of 64 KT patients were enrolled and 43 first hospitalization events occurred. Fasting blood samples were obtained and serum 3-MH level was performed with high-performance liquid chromatography and mass spectrometry. Associations between serum 3-MH levels and first hospitalization over a 5-year follow-up period were examined. Results: Compared with patients without hospitalization, the 64 patients with KT revealed higher diabetes (P =.012) and hypertension (P =.006) prevalence, higher body fat mass (P =.012) and systolic blood pressure (P =.002), higher serum blood urea nitrogen (BUN) levels (P =.003), and lower serum 3-MH levels (P =.001). Statistical analysis revealed that serum 3-MH (95% confidence interval [CI]: 0.902-0.986, P =.010) and serum BUN (95% CI: 1.003-1.040, P =.022) levels were independently associated with first hospitalization events in patients with KT. Kaplan-Meier analysis showed a greater cumulative incidence of first hospitalization events in the patients with lower 3-MH levels (≤5.91 ng/mL) than that in those with higher 3-MH levels (P =.014; log-rank test). Conclusions: Low serum 3-MH levels are associated with increased first hospitalization risk in KT recipients.
AB - Background: Low protein intake and increased muscle breakdown are associated with increased mortality risk in patients with kidney transplantation (KT). 3-methylhistidine (3-MH), a nonproteinogenic amino acid residue, is an index of muscle breakdown. the present study investigated the association between serum 3-MH levels and subsequent first hospitalization events in patients with KT. Methods: A total of 64 KT patients were enrolled and 43 first hospitalization events occurred. Fasting blood samples were obtained and serum 3-MH level was performed with high-performance liquid chromatography and mass spectrometry. Associations between serum 3-MH levels and first hospitalization over a 5-year follow-up period were examined. Results: Compared with patients without hospitalization, the 64 patients with KT revealed higher diabetes (P =.012) and hypertension (P =.006) prevalence, higher body fat mass (P =.012) and systolic blood pressure (P =.002), higher serum blood urea nitrogen (BUN) levels (P =.003), and lower serum 3-MH levels (P =.001). Statistical analysis revealed that serum 3-MH (95% confidence interval [CI]: 0.902-0.986, P =.010) and serum BUN (95% CI: 1.003-1.040, P =.022) levels were independently associated with first hospitalization events in patients with KT. Kaplan-Meier analysis showed a greater cumulative incidence of first hospitalization events in the patients with lower 3-MH levels (≤5.91 ng/mL) than that in those with higher 3-MH levels (P =.014; log-rank test). Conclusions: Low serum 3-MH levels are associated with increased first hospitalization risk in KT recipients.
UR - http://www.scopus.com/inward/record.url?scp=85089087571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089087571&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2020.06.036
DO - 10.1016/j.transproceed.2020.06.036
M3 - Article
C2 - 32771248
AN - SCOPUS:85089087571
SN - 0041-1345
VL - 52
SP - 3214
EP - 3220
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 10
ER -
